• Sciwind Biosciences Secures US$37 Million Series B Financing prnasia
    February 19, 2021
    Hangzhou Sciwind Biosciences Co., Ltd. (Sciwind), a clinical-stage, fast-growing biopharmaceutical company focusing on research and development of innovative biologics, today announced the closing of an US$37 Million series B financing.
PharmaSources Customer Service